1. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors
- Author
-
Mona Malz, Volker Ehemann, Hendrik Bläker, Peter Schirmacher, Andreas Harjung, Lars Fischer, Marco Breinig, Michael A. Kern, Philipp Mayer, Jens Werner, Frank Bergmann, Hans Scherübl, and Sarah Britsch
- Subjects
Adult ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,Cell cycle checkpoint ,Adolescent ,Cell Survival ,Endocrinology, Diabetes and Metabolism ,Lactams, Macrocyclic ,Apoptosis ,Biology ,Mice ,Young Adult ,Endocrinology ,Heat shock protein ,Cell Line, Tumor ,medicine ,Benzoquinones ,Multiple Endocrine Neoplasia Type 1 ,Animals ,Humans ,Viability assay ,HSP90 Heat-Shock Proteins ,RNA, Messenger ,Aged ,Aged, 80 and over ,Antibiotics, Antineoplastic ,Middle Aged ,Hsp90 ,Gene Expression Regulation, Neoplastic ,Pancreatic Neoplasms ,Oncology ,Cell culture ,Doxorubicin ,Cancer research ,biology.protein ,Immunohistochemistry ,Tumor necrosis factor alpha ,Female ,Fluorouracil - Abstract
Pancreatic endocrine tumors (PET) represent a heterogenous group of neoplasms. Although surgical resection is considered a safe and effective treatment for many PET, therapeutic options for inoperable and progressive PET are limited. The expression of heat-shock protein (HSP) 90 was investigated in 120 clinically and pathomorphologically well-characterized PET from 84 patients using immunohistochemistry. In addition, in 19 snap–frozen PET and in three healthy pancreatic tissues, we performed immunoblot analyses, and in 15 snap–frozen PET and in three healthy pancreatic tissues, we investigated the expression of HSP90 isoforms by means of semiquantitative RT-PCR. Functional tests were conducted using the human pancreas carcinoid cell line BON and the mouse insulinoma cell line β-TC-3. HSP90 was expressed in 95% of the PET patients. The transcript levels of the HSP90 isoforms HSP90α, HSP90β, glucose-related protein 94, and TNF receptor-associated protein 1 were significantly increased in PET compared with non-neoplastic pancreatic tissues. The treatment of the cell lines BON and β-TC-3 with the HSP90 inhibitors 17-allylamino-17-demethoxygeldanamycin and 17-dimethylaminoethylamino-17-demethoxy-geldanamycin resulted in significant, dose-dependent reduction of cell viability, cell cycle arrest, and increased apoptosis. Furthermore, HSP90 inhibition induced the degradation and inactivation of several oncogenetic HSP90 client proteins in a time- and dose-dependent manner. HSP90 inhibitors increased the therapeutic effects of doxorubicin and 5-fluorucacil in BON and β-TC-3 cells. HSP90 is expressed in the vast majority of PET and its inhibition reveals significant treatment effects in vitro. Thus, HSP90 qualifies as a promising new target.
- Published
- 2011